- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02460211
Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D (ASSESS-D)
1 april 2021 bijgewerkt door: Intermountain Health Care, Inc.
Each patient who is admitted for preoperative preparation for elective open heart surgery at Intermountain Medical Center will be invited to participate in this study.
After a written informed consent is obtained, patients meeting inclusion/exclusion criteria will be randomized 1:1 to the treatment arm or placebo/control arm.
Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
The first dose will be given the evening before surgery.
The second and third doses will be given either orally or per NG tube on the mornings of post-op days 1 and 2. Blood will be obtained at the following time periods: 1) At baseline pre-procedure 12 to 18 hours before planned surgery; 2) Post-operative day 1, 12 to 24 hours after surgery; 3) 48 hours after surgery; 4) 72 hours after surgery; 5) At discharge (estimated to be between 5-8 days after surgery); and 6) At the 6-month follow-up visit (post-surgery).
Plasma levels of 25(OH) vitamin D will be measured on each sample.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Each patient who is admitted for preoperative preparation for elective open heart surgery at Intermountain Medical Center will be invited to participate in this study.
The patient's history and medical records will be reviewed and data gathered will be used to evaluate the patient's relationship to inclusion and exclusion criteria.
After a written informed consent is obtained, subjects will be randomized 1:1 to the treatment arm or placebo/control arm.
Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
The first dose will be given the evening before surgery.
The second and third doses will be given either orally or per NG tube on the mornings of post-op days 1 and 2. Approximately 15-20 ml (about one tablespoon) of blood will be obtained at the following time periods (+/- 4 hours): 1) At baseline pre-procedure 12 to 18 hours before planned surgery; 2) Post-operative day 1, 12 to 24 hours after surgery; 3) 48 hours after surgery; 4) 72 hours after surgery; 5) At discharge (estimated to be between 5-8 days after surgery); and 6) At the 6-month follow-up visit (post-surgery).
Each blood sample will be transported to The Center for Molecular and Genetic Research at LDS Hospital Cardiovascular Genetics Laboratory for preparation and storage.
Plasma levels of 25(OH) vitamin D will be measured on each sample.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
150
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Utah
-
Murray, Utah, Verenigde Staten, 84143
- Intermountain Heart Institute
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Male or female >= 18 years of age
- Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures
- Subject is scheduled for elective open heart surgery at Intermountain Medical Center
- Subject is relatively stable as assessed by the Principal Investigator
Exclusion Criteria:
- Inability or refusal of the patient and/or the patient's legally acceptable representative to provide written informed consent for any reason.
- History of previous vitamin D supplementation > 1,000 units of vitamin D3 per day within the past three months.
- Evidence of hypercalcemia on screening labs (> 10.5 milligrams per deciliter of blood).
- Any scheduled cardiac surgical procedure that does not require open thoracotomy (the reason for this exclusion is that the study design requires that the patients will undergo a significantly stressful procedure, which can be generally guaranteed if the patient undergoes open thoracotomy).
- Known allergic reaction or other intolerance to oral vitamin D3.
- Pregnant and/or lactating women and women of child bearing potential who are not using acceptable means of contraception. Women of childbearing potential must be using adequate measures of contraception (as determined by the Principal Investigator) to avoid pregnancy and should be highly unlikely to conceive during the study period. Women of childbearing potential must have a negative pregnancy test at screen.
- Subject participation in previous investigational interventional studies within 30 days of the current study.
- Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the clinical trial.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: Treatment
Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
|
Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
The first dose will be given the evening before surgery.
The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
|
Placebo-vergelijker: Placebo/Control Arm
Those randomized to the control arm will receive three oral placebo doses.
|
Those randomized to the control arm will receive three placebo doses.
The first dose will be given the evening before surgery.
The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Changes in 25(OH) vitamin D levels (ng/ml) between baseline (pre-surgery) and 72 hours post-surgery.
Tijdsspanne: 72 hours
|
72 hours
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Comparison of 25(OH) vitamin D levels (ng/ml) between baseline and other time points.
Tijdsspanne: 12-24 hrs, 48 hrs, discharge (approximately 5-8 days post-surgery), 6 months
|
Subjects will be re-assessed on post-operative day 1 (12-24 hours after surgery), then at 48 and 72 hours post-surgery, at discharge (approximately 5-8 days post-surgery), and at a 6 month post-surgery follow-up visit.
|
12-24 hrs, 48 hrs, discharge (approximately 5-8 days post-surgery), 6 months
|
Percent differences in adverse clinical outcomes between the vitamin D3 supplementation treatment and placebo arms.
Tijdsspanne: 6 months
|
Clinical outcomes that will be monitored include: death, myocardial infarction, stroke, repeat coronary revascularization or hospitalization for heart failure, worsening of renal function, hospitalization for pneumonia or other acute systemic infection or any other serious adverse clinical event.
|
6 months
|
Time to adverse clinical events stratified by vitamin D3 supplementation and placebo arms.
Tijdsspanne: 6 months
|
Clinical outcomes that will be monitored include: death, myocardial infarction, stroke, repeat coronary revascularization or hospitalization for heart failure, worsening of renal function, hospitalization for pneumonia or other acute systemic infection or any other serious adverse clinical event.
|
6 months
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Hoofdonderzoeker: Joseph B Muhlestein, MD, Intermountain Health Care, Inc.
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 juli 2015
Primaire voltooiing (Werkelijk)
1 oktober 2018
Studie voltooiing (Werkelijk)
1 oktober 2020
Studieregistratiedata
Eerst ingediend
8 april 2015
Eerst ingediend dat voldeed aan de QC-criteria
29 mei 2015
Eerst geplaatst (Schatting)
2 juni 2015
Updates van studierecords
Laatste update geplaatst (Werkelijk)
5 april 2021
Laatste update ingediend die voldeed aan QC-criteria
1 april 2021
Laatst geverifieerd
1 april 2021
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1040458
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Vitamin D3
-
Aalborg UniversityAalborg University Hospital; CCBR Aalborg A/S, Aalborg, DenmarkVoltooidMigraine volgens de criteria van de International Headache Society (IHS) (ICHD-II)Denemarken
-
Alcon ResearchVoltooidVisieVerenigde Staten
-
Tata Memorial CentreWerving
-
Cedars-Sinai Medical CenterBeëindigdVitamine D-tekort | Ziekte van CrohnVerenigde Staten
-
University of California, San FranciscoVoltooid
-
Aga Khan UniversityVoltooidVitamine D-tekortPakistan
-
University of NottinghamAbbeyfieldVoltooidSarcopenie | SpieratrofieVerenigd Koninkrijk
-
Moscow Clinical Scientific CenterWervingCecal neoplasmata | Colonneoplasmata KwaadaardigRussische Federatie
-
Medical University of South CarolinaThrasher Research FundVoltooidVitamine D-tekort | ZwangerschapVerenigde Staten